Background/aims: Soft tissue sarcomas form a heterogeneous group of mesenchymal neoplasm that can arise almost anywhere in the body. Treatment and prognosis are interdependent factors. Accurate determination of prognosis is critical in order to guide therapeutic decisions. This study aimed to analyze some prognostic factors in soft tissue sarcoma. Methods used to collect evidences: Visiting sites on the internet to collect and analyze researches concerned with studying the pathological prognostic variables and definition of a histopathological grading system of soft tissue sarcoma within a scope including: The last 10 years, randomized controlled studies, English language journals, internet sites, Egyptian Universities Libraries, USCAP (United States and Canadian Academy of Pathology), Pubmed-line, Science direct, Yahoo and Scholar Google. Results: Many prognostic factors for metastasis have been proposed, such as patient age and sex, tumor depth, location, size, histotype, malignancy grade, mitotic rate, microscopic tumor necrosis, vascular invasion, DNA-ploidy, S-phase fraction (SPF), and a number of molecular markers. From this overview, we can say that histological grade is the most important prognostic factor. Ultimately, however, the true biological grade of sarcoma is multi-factorial and depends on the complex interplay of histological type, tumor size, tumor depth (in relation to fascia), tumor location, and presence of necrosis, histological grade, and clinical stage. Understanding the relative importance of each of these factors in a given tumor sufficiently well to allow reliable prognostication in all soft tissue sarcomas at present remains a somewhat hope. Conclusion: High-grade tumors, characterized by poor cellular differentiation, are associated with a significantly higher incidence of local recurrence and distant metastasis. Tumor size is an important determinant of survival. Patients with soft tissue sarcomas less than 5 cm in greatest diameter have a metastasis-free five-year survival rate of 81 % regardless of tumor grade